JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, we identify mutations in both tumor-suppressor genes, e.g., ABL1, JAK2, MAP2K1, and KIT [38], from poor responders in CML, suggesting that these are two of the key mechanisms by which tumor cells evolve to acquire drug resistance.